HER2 YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy
Samanthi A. Perera, Danan Li, Takeshi Shimamura et al. · Proceedings of the National Academy of Sciences · 2009
Mutations in the HER2 kinase domain have been identified in human clinical lung cancer specimens. Here we demonstrate that inducible expression of the most common HER2 mutant (HER2(YVMA)) in mouse lung epithelium causes invasive adenosquamous carcinomas restricted to proximal and distal bronchioles. Continuous expression of HER2(YVMA) is essential for tumor maintenance, suggesting a key role for HER2 in lung adenosquamous tumorigenesis. Preclinical studies assessing the in vivo effect of erlotinib, trastuzumab, BIBW2992, and/or rapamycin on HER2(YVMA) transgenic mice or H1781 xenografts with documented tumor burden revealed that the combination of BIBW2992 and rapamycin is the most effective treatment paradigm causing significant tumor shrinkage. Immunohistochemical analysis of lung tumors treated with BIBW2992 and rapamycin combination revealed decreased phosphorylation levels for proteins in both upstream and downstream arms of MAPK and Akt/mTOR signaling axes, indicating inhibition of these pathways. Based on these findings, clinical testing of the BIBW2992/rapamycin combination in non-small cell lung cancer patients with tumors expressing HER2 mutations is warranted.
Cited by 184 works. doi:10.1073/pnas.0808930106
Authors
- Samanthi A. Perera
- Danan Li
- Takeshi Shimamura
- Maria Gabriela Raso
- Hongbin Ji
- Liang Chen
- Christa L. Borgman
- Sara Zaghlul
- Shigeto Kubo
- Masaya Takahashi
- Lucian R. Chirieac
- Robert F. Padera
- Roderick Terry Bronson
- Geoffrey Ira Shapiro
- Heidi E. Greulich
- Matthew M. Meyerson
- Ulrich Gürtler
- Pilar Garin Chesa
- Flavio Solca
References
- Untangling the ErbB signalling network
- Intragenic ERBB2 kinase mutations in tumours
- ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies
- Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
- Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes
- Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers?
- Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts
- Bronchial and Peripheral Murine Lung Carcinomas Induced by T790M-L858R Mutant EGFR Respond to HKI-272 and Rapamycin Combination Therapy